Skip to main content
. 2022 Mar 2;76(4):720–729. doi: 10.1093/cid/ciac130

Figure 2.

Figure 2.

Adjusted treatment difference in virologic outcomes at week 48 in the ITT-E population. aPrimary endpoint (Snapshot virologic failure, ITT-E). bBased on Cochran-Mantel-Haenszel stratified analysis (DTG/3TC − CAR) adjusting for baseline third agent class. Abbreviations: CAR, current antiretroviral regimen; DTG/3TC, dolutegravir/lamivudine; HIV-1, human immunodeficiency virus 1; ITT-E, intention-to-treat–exposed.